Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams

cryptocurrency 1 month ago
Flipboard
Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. …
Read Entire Article